CPT code 82553 represents a laboratory assay for the MB fraction of creatine kinase (CK-MB), an enzyme fraction commonly measured when myocardial injury is suspected. As a targeted cardiac biomarker test, CK-MB has clinical relevance for detecting and timing cardiac muscle damage, complementing other biomarkers used in acute care. Nationally, CK-MB testing remains part of cardiac diagnostic workflows in many hospitals and outpatient laboratories, influencing laboratory utilization, reporting, and reimbursement policy considerations.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for CK-MB testing, the typical service setting where CPT code 82553 is billed, and the common billing modifiers associated with laboratory services. The publication outlines benchmarking and coverage context for major national payers, notes typical sites of service, and summarizes how CPT code 82553 fits within cardiac diagnostic test panels.

This summary provides clinicians, laboratory managers, and billing professionals with concise context on when CPT code 82553 is used, the service environments where it is performed, and the payer landscape relevant to national billing and policy considerations. Data not available in the input include specific payer coverage policies, pricing benchmarks, and related ICD-10 codes.